Transitioning patients from cangrelor to clopidogrel: Pharmacodynamic evidence of a competitive effect

Thrombosis Research

Volumn 121, Issue 4, 2008, Pages 527-534

  Steinhubl, Steven R ^a   Oh, Jennifer J ^a   Oestreich, Julie H ^a   Ferraris, Suellen ^a   Charnigo, Richard ^a   Akers, Wendell S ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Angioplasty; Cangrelor; Coronary disease; P2Y12 inhibition; Platelets

Indexed keywords

CANGRELOR; CLOPIDOGREL; PADGEM PROTEIN;

ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG MECHANISM; FLOW CYTOMETRY; HUMAN; HUMAN EXPERIMENT; IMPEDANCE; LOADING DRUG DOSE; NORMAL HUMAN; PRIORITY JOURNAL; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION;

ADENOSINE DIPHOSPHATE; ADENOSINE MONOPHOSPHATE; ADOLESCENT; ADULT; CYCLOOXYGENASE INHIBITORS; FEMALE; HUMANS; MALE; MIDDLE AGED; P-SELECTIN; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; RECEPTORS, PURINERGIC P2; TICLOPIDINE;

EID: 38649113576     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2007.05.020     Document Type: Article

References (14)

1. Newby L.K., Roe M.T., Chen A.Y., Ohman E.M., Christenson R.H., Pollack Jr. C.V., et al. Frequency and clinical implications of discordant creatine kinase-MB and troponin measurements in acute coronary syndromes. J Am Coll Cardiol 47 (2006) 312-318
2. Leong J.Y., Baker R.A., Shah P.J., Cherian V.K., and Knight J.L. Clopidogrel and bleeding after coronary artery bypass graft surgery. Ann Thorac Surg 80 (2005) 928-933
3. Hochholzer W., Trenk D., Frundi D., Blanke P., Fischer B., Andris K., et al. Time dependence of platelet inhibition after a 600-mg loading dose of clopidogrel in a large, unselected cohort of candidates for percutaneous coronary intervention. Circulation 111 (2005) 2560-2564
4. Pereillo J.M., Maftouh M., Andrieu A., Uzabiaga M.F., Fedeli O., Savi P., et al. Structure and stereochemistry of the active metabolite of clopidogrel. Drug Metab Dispos 30 (2002) 1288-1295
5. Ding Z., Kim S., Dorsam R.T., Jin J., and Kunapuli S.P. Inactivation of the human P2Y12 receptor by thiol reagents requires interaction with both extracellular cysteine residues, Cys17 and Cys270. Blood 101 (2003) 3908-3914
6. Zimmermann H. Extracellular metabolism of ATP and other nucleotides. Naunyn Schmiedebergs Arch Pharmacol 362 (2000) 299-309
7. Capone M.L., Sciulli M.G., Tacconelli S., Grana M., Ricciotti E., Renda G., et al. Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects. J Am Coll Cardiol 45 (2005) 1295-1301
8. Catella-Lawson F., Reilly M.P., Kapoor S.C., Cucchiara A.J., DeMarco S., Tourner B., et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 345 (2001) 1809-1817
9. Pedersen A.K., and FitzGerald G.A. Dose-related kinetics of aspirin. Presystemic acetylation of platelet cyclooxygenase. N Engl J Med 311 (1984) 1206-1211
10. Benedek I.H., Joshi A.S., Pieniaszek H.J., King S.-Y.P., and Kornhauser D.M. Variability in the pharmacokinetics and pharmacodynamics of low dose aspirin in healthy male volunteers. J Clin Pharmacol 35 (1995) 1181-1186
11. Savi P., Herbert J.M., Pflieger A., Dol F., Delebasse D., Combalbert J., et al. Importance of hepatic metabolism in the antiaggregating activity of the thienopyridine clopidogrel. Biochem Pharmacol 44 (1992) 527-532
12. Wihlborg A.K., Wang L., Braun O.O., Eyjolfsson A., Gustafsson R., Gudbjartsson T., et al. ADP receptor P2Y12 is expressed in vascular smooth muscle cells and stimulates contraction in human blood vessels. Arterioscler Thromb Vasc Biol 24 (2004) 1810-1815
13. Taubert D., Kastrati A., Harlfinger S., Gorchakova O., Lazar A., von Beckerath N., et al. Pharmacokinetics of clopidogrel after administration of a high loading dose. Thromb Haemost 92 (2004) 311-316
14. Savi P., and Herbert J.M. Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis. Semin Thromb Hemost 31 (2005) 174-183